Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1799 |
Name | islet cell tumor |
Definition | A pancreatic cancer that is located_in the pancreatic islet cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:10165 |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer islet cell tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TSC1 inact mut | N/A | islet cell tumor | not applicable | detail... |
TSC2 inact mut | N/A | islet cell tumor | not applicable | detail... |
VHL inact mut | N/A | islet cell tumor | not applicable | detail... |
VHL mutant | Belzutifan | islet cell tumor | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01465659 | Phase Ib/II | Pazopanib + Temozolomide | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01525082 | Phase II | Bevacizumab + Capecitabine + Temozolomide | Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | Completed | USA | 0 |
NCT01525550 | FDA approved | Sunitinib | A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | Completed | USA | SVK | ROU | NOR | ITA | HUN | FRA | ESP | CZE | BEL | AUS | 4 |
NCT01603004 | Phase I | Everolimus Sunitinib | Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors | Completed | USA | 0 |
NCT01784861 | Phase Ib/II | Everolimus + Vorolanib | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | Terminated | USA | 0 |
NCT02031536 | Phase II | Everolimus | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | Terminated | USA | 0 |
NCT02101918 | Phase II | Aflibercept | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02315625 | Phase II | Everolimus Sunitinib | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02831179 | Phase I | Capecitabine + Temozolomide + Veliparib | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | Withdrawn | 0 | |
NCT03095274 | Phase II | Durvalumab Tremelimumab | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) | Completed | ESP | 0 |
NCT03351296 | Phase II | Bevacizumab + Capecitabine + Temozolomide Bevacizumab + Fluorouracil + Leucovorin + Streptozocin | Two Chemotherapy Regimens Plus or Minus Bevacizumab (BETTER 2) | Active, not recruiting | FRA | 0 |
NCT03736720 | Phase II | Fluorouracil + Leucovorin + Liposomal irinotecan | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | Active, not recruiting | USA | 0 |
NCT04086485 | Phase Ib/II | lutetium Lu 177 dotatate + Olaparib | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | Recruiting | USA | 0 |
NCT04609592 | Phase I | lutetium Lu 177 dotatate | Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Recruiting | USA | 0 |
NCT04893785 | Phase II | Cabozantinib + Temozolomide | A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM) | Recruiting | ITA | 0 |
NCT04924075 | Phase II | Belzutifan | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015) | Recruiting | USA | TUR | SWE | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 4 |
NCT06472388 | Phase II | Everolimus | Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors (EVENET) | Recruiting | BRA | 0 |
NCT06663072 | Phase I | Fulvestrant + lutetium Lu 177 dotatate | Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors | Not yet recruiting | USA | 0 |